Discovery of a sulfotyrosine-motif in the human TrkB extracellular domain required for agonist activation

Briggs, D. C.; Duffy, R. T.; Ateaque, S.; Maslen, S.; Naharaj, H.; Barde, Y.-A.; DiStefano, P. S.; Lindsay, R. M.; Armstrong, P. C.; Peach, C. J.; McDonald, N. Q.

doi:10.64898/2026.05.19.725324

bioRxiv · 10.64898/2026.05.19.725324

Discovery of a sulfotyrosine-motif in the human TrkB extracellular domain required for agonist activation

Briggs, D. C.·Duffy, R. T.·Ateaque, S.·Maslen, S.·Naharaj, H.·Barde, Y.-A.·DiStefano, P. S.·Lindsay, R. M.·Armstrong, P. C.·Peach, C. J.·McDonald, N. Q.

View original source ↗Export metadata ↓

Abstract

The brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B (TrkB) signalling axis is a key effector of synaptic plasticity and neuroprotection. While TrkB activation is a major objective towards preventing dysfunction of the nervous system, it cannot be reached with exogenous BDNF administration given the unfavourable physiochemical properties of BDNF. In addition, BDNF also activates a tumour necrosis factor pathway by binding to the neurotrophin receptor p75. The TrkB agonist ZEB85 provides an alternative route to the selective activation of TrkB. We report here the structural basis for the interaction between human TrkB, and both ZEB85 and BDNF, and reveal that a sulfated tyrosine modification is indispensable for ZEB85 activation of TrkB signalling. Using structure-guided BDNF- and ZEB85-binding deficient TrkB mutants, we assessed their ability to sequester ligands from full-length TrkB in cultured human neurons. We found that the BDNF binding site extends into the extracellular juxtamembrane domain of TrkB but does not require the sulfotyrosine at residue 400 to activate TrkB. Together with biophysical analysis and AlphaFold modelling these results also explain how BDNF can displace ZEB85 from TrkB through an overlapping epitope. Our findings reveal unique features of TrkB, not present in the related neurotrophin receptors TrkA and TrkC, and suggest new directions to explore the role of sulfotyrosine in TrkB signalling and identify new TrkB-specific protein ligands. One Sentence SummaryInvestigation of the mechanism of action of TrkB agonist ZEB85 extends molecular understanding of TrkB activation.

Explore related subjects

biochemistry Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Briggs, D. C., Duffy, R. T., Ateaque, S., Maslen, S., Naharaj, H., Barde, Y.-A., DiStefano, P. S., Lindsay, R. M., Armstrong, P. C., Peach, C. J., McDonald, N. Q.. 2026-05-21. Discovery of a sulfotyrosine-motif in the human TrkB extracellular domain required for agonist activation. https://doi.org/10.64898/2026.05.19.725324

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Probing the sequence variability tolerance in a de novo α-helical barrel biocatalyst

De novo-designed enzymes have recently achieved high catalytic activity and stereoselectivity while demonstrating exceptional thermostability in entirely novel protein scaffolds. Among these, -helical barrel protein scaffolds are attractive structures for biocatalysis due to their structural simplicity, high thermostability, and rationalizable sequence patterning. However, enabling major structural reengineering of these scaffolds while maintaining the structure, stability and catalytic activity while also improving soluble protein production remain major challenges and pose the fundamental question how engineerable a de novo backbone-sequence pair is. Here, we combine deep learning based and classic computational protein design to modify and optimize de novo -helical barrel biocatalysts. Using the previously reported six-helical barrel 6H5L as a model scaffold, AlphaFold2-guided RosettaRemodel enabled the design of a truncated variant, whose crystal structure closely matches the design model. Additional sequence-redesign using ProteinMPNN generated a variant with a tenfold increase of soluble protein yield in Escherichia coli. Biochemical, biophysical, and structural analyses showed that both variants retained the overall barrel architecture, high thermal stability, and catalytic activity for both purified protein and whole-cell systems. Detailed kinetic analysis on the variants showed both variation in kcat and Km, reflecting changes in catalytic turnover and substrate binding. Together, these approaches provide new insights and possibilities for the further engineering of functional de novo -helical barrels, their ability to withstand dramatically large sequence changes and their broader application in biocatalysis and biotechnology.

biochemistry↗

bioRxiv2026

Conjunctive Targeting Links Drug Synergy to Emergent Proteome Structural States

Combinatorial therapies are widely used in the treatment of acute myeloid leukemia (AML) to address disease heterogeneity, adaptive resistance, and rewired signaling and metabolic states. Yet drug prioritization remains largely guided by clinical or phenotypic evidence, while the molecular mechanisms underlying effective drug combinations remain incompletely defined. To narrow this gap, we developed Combinatorial high-ratio Partial proteolysis with reference PRoteome Analysis (CoPPRA), a structural proteomics workflow based on limited proteolysis of cell lysates that profiles drug-associated changes in regional protein accessibility at peptide-level resolution. Here, we applied CoPPRA to ruxolitinib and ulixertinib, individually and in combination, in AML-related cell lysates. Our findings extend conjunctive targeting (CT), a recently proposed mechanism of combinatorial drug action in which combined exposure produces protein targeting patterns not observed with either drug alone. Previously identified through combination-associated changes in protein solubility/stability, CT is examined here at peptide-level resolution through regional differences in proteolytic accessibility. The ruxolitinib-ulixertinib combination produced broad peptide-level accessibility changes, including a subset meeting the predefined criteria for CT. CT candidates predominantly exhibited regional accessibility changes, with altered peptide regions occurring against comparatively small changes across the remaining quantified peptides from the same proteins. MAP2K1 and ATP6V1G1 showed pronounced differences between overlapping peptide sequences, highlighting localized variation in combination-associated accessibility, including an ATP6V1G1 peptide mapping to an annotated helical region. Combination-associated increases in peptide signals were also observed in PIK3R1, BRD4, and PTPN11, linking regional accessibility changes to signaling and transcriptional regulators relevant to AML. Functional enrichment and network analyses further implicated nucleotide and glucose metabolism, ficolin-1-rich granules, ribosome-associated processes, and phagocytic vesicles. These results extend conjunctive targeting from protein-level solubility/stability changes to regional differences in proteolytic accessibility, showing that combination-associated effects can be concentrated within specific peptide regions rather than distributed uniformly across proteins. More broadly, CoPPRA provides a peptide-resolved approach for investigating the molecular features of combinatorial drug action and prioritizing protein regions for subsequent mechanistic validation.

biochemistry↗

bioRxiv2026

Structural and biochemical characterisation of an iterative GCN5-related N-acetyltransferase required for fungal siderophore tailoring

Siderophore-mediated iron acquisition is essential for fungal survival, particularly under iron-limiting conditions. In Aspergillus fumigatus, SidG, a member of the GCN5-related N-acetyltransferase (GNAT) superfamily, catalyses the final step in the biosynthesis of the extracellular siderophore triacetylfusarinine C (TAFC) through sequential acetylation of the precursor fusarinine C (FsC). However, the timing, catalytic mechanism, and functional significance of this modification are not fully understood. Here, we reconstituted SidG activity in vitro and combined native mass spectrometry, X-ray crystallography, molecular dynamics simulations, and site-directed mutagenesis to investigate its catalytic properties. Our analyses demonstrate that SidG selectively binds acetyl-CoA from the cellular milieu and iteratively acetylates the FsC scaffold prior to iron chelation. Structural, biochemical, and molecular dynamics analyses support a direct transfer mechanism, identify key catalytic residues, and demonstrate the strict selectivity of SidG for short-chain acyl-CoA donors. Together, these findings establish the molecular basis for SidG-dependent siderophore tailoring and expand our understanding of GNAT-catalysed transformations in fungal natural product biosynthesis.

biochemistry↗